Alberta Investment Management Corp Acquires 36,500 Shares of DexCom, Inc. (NASDAQ:DXCM)

Alberta Investment Management Corp boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 13.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 302,357 shares of the medical device company’s stock after acquiring an additional 36,500 shares during the period. Alberta Investment Management Corp owned 0.08% of DexCom worth $23,514,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Versant Capital Management Inc bought a new stake in DexCom in the 4th quarter valued at $25,000. Heck Capital Advisors LLC acquired a new position in DexCom in the 4th quarter valued at $38,000. MassMutual Private Wealth & Trust FSB grew its holdings in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new position in DexCom in the 3rd quarter valued at $57,000. Finally, Park Place Capital Corp grew its holdings in DexCom by 3,516.7% in the 4th quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock valued at $68,000 after buying an additional 844 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. increased their target price on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $99.06.

DexCom Trading Up 1.6 %

NASDAQ DXCM opened at $90.53 on Wednesday. The business has a 50 day simple moving average of $82.65 and a 200 day simple moving average of $75.62. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The stock has a market capitalization of $35.36 billion, a P/E ratio of 63.31, a P/E/G ratio of 2.31 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts expect that DexCom, Inc. will post 1.98 earnings per share for the current year.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,083 shares of company stock valued at $3,309,794. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.